Chung, Hattie http://orcid.org/0000-0001-8417-5606
Parkhurst, Christopher N.
Magee, Emma M. http://orcid.org/0000-0001-9285-2451
Phillips, Devan
Habibi, Ehsan
Chen, Fei http://orcid.org/0000-0003-2308-3649
Yeung, Bertrand Z.
Waldman, Julia
Artis, David
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (5RM1 HG006193, 5RM1 HG006193)
Article History
Received: 11 January 2021
Accepted: 19 August 2021
First Online: 4 October 2021
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and, until 31 August 2020, was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From 1 August 2020, A.R. is an employee of Genentech. From May 2021, D.P. is an employee of Genentech. B.Z.Y. was formerly an employee of BioLegend and is now an employee of Spatial Genomics. The remaining authors declare no competing interests.